(TOI) The Oncology Institute, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(TOI) The Oncology Institute, Inc. Complete Analysis Pack
The Oncology Institute: Business Model Canvas at a Glance
Unlock the strategic blueprint behind The Oncology Institute, Inc.’s business model. This concise Business Model Canvas shows how the company creates value, serves patients, and builds partnerships in a highly specialized healthcare market. It’s a smart resource for investors, analysts, and strategists who want a clear edge. Get the full canvas for deeper, company-specific insight.
Partnerships
Referral physicians and hospitals
The Oncology Institute, Inc. relies on referral physicians, hospitals, and surgeons to route cancer patients into care quickly and keep treatment plans aligned across inpatient and outpatient settings. With U.S. cancer cases still above 2 million a year, these partners are key to timely diagnosis, smoother handoffs, and better continuity of care.
Payers and health plans
Commercial insurers, Medicare, and Medicaid are the core reimbursement partners for The Oncology Institute, Inc.; Medicare covers about 66 million people and Medicaid about 79 million, so payer policy directly shapes access and collections. Strong contract terms and prior-authorization paths matter because coverage decisions can change visit volume, drug use, and cash timing across a multi-site oncology network.
Pharmaceutical and specialty drug suppliers
Pharmaceutical and specialty drug suppliers keep The Oncology Institute, Inc.'s infusion and dispensing sites stocked with oncology and supportive drugs, so treatment stays aligned with patient schedules. These partners are central to on-site medication fulfillment, especially for therapies that can cost thousands of dollars per dose and need tight handling and delivery control.
Laboratory and pathology providers
The Oncology Institute, Inc. relies on laboratory and pathology providers to confirm cancer type, guide treatment choice, and track response and safety through repeat bloodwork and tissue review. These partners keep evidence-based oncology workflows moving, especially when biomarker and toxicity checks change therapy fast.
- Support diagnosis and staging
- Enable treatment selection
- Track response and safety
- Back evidence-based care
Clinical trial sponsors and research partners
The Oncology Institute, Inc. works with clinical trial sponsors and research partners to run studies across its oncology network; sponsors supply protocols, funding, and oversight, while TOI handles site execution and patient enrollment. These ties help eligible patients access investigational therapies faster, and they support a higher-margin research revenue stream tied to sponsor-backed trials.
- Protocol, funding, oversight
- Patient access to new therapies
- Supports trial-based revenue
Payer Partnerships Drive Oncology Institute’s Cash Flow
The Oncology Institute, Inc. depends on referral doctors, hospitals, payers, drug makers, labs, and trial sponsors to move patients from diagnosis to treatment and to keep cash flow tied to covered care. Medicare serves about 66 million people and Medicaid about 79 million, so payer terms are central to access and collections.
| Partner | Why it matters | Key data |
|---|---|---|
| Payers | Reimbursement | 66M Medicare; 79M Medicaid |
| Suppliers | Drug access | Infusion and specialty meds |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas of The Oncology Institute, Inc. for investors and analysts.
Customizable Excel Spreadsheet
Quickly spot The Oncology Institute, Inc.’s key business model pain points in one clear, editable snapshot.
Reference Sources
Provides a traceable source trail for The Oncology Institute, Inc., strengthening credibility and helping investors verify key assumptions quickly.
Activities
Medical oncology care
Medical oncology care is The Oncology Institute, Inc.'s core activity: physician-led diagnosis review, treatment planning, and ongoing management for adult and senior cancer patients. In fiscal 2025, this clinic-first model remained the engine of revenue, with care delivered through a large outpatient network that keeps treatment close to home.
On-site infusion and dispensing
In fiscal 2025, The Oncology Institute, Inc. keeps infusion and medication dispensing in the same care setting, so patients can receive and fill treatment without leaving the clinic. This integrated model supports coordinated therapy delivery, tighter care control, and less friction for patients and providers.
Radiation therapy services
The Oncology Institute, Inc. uses radiation therapy as part of its integrated cancer care, often paired with systemic treatment to lift response rates; about 50% of cancer patients receive radiation at some point in care. This adds another treatment path for patients and helps Company Name cover more disease stages.
Clinical trial management
TOI manages clinical trial operations across its care network, including patient screening, protocol execution, and study coordination. In FY2025, this keeps advanced cancer therapies closer to patients while also supporting research access across the company’s oncology sites.
- Screen patients for trial fit
- Run protocol steps on site
- Coordinate studies across locations
Palliative and outpatient support programs
The Oncology Institute, Inc. uses palliative care and outpatient stem cell transplant and transfusion services to ease symptoms, reduce treatment side effects, and keep supportive care close to the patient. These services improve comfort and care continuity across the oncology journey, especially when patients need frequent follow-up and coordinated symptom management.
- Manages pain, nausea, and other side effects
- Supports outpatient transplant and transfusion continuity
TOI’s FY2025 Care Model: Outpatient Oncology, Infusions, and Trials
In fiscal 2025, The Oncology Institute, Inc. centered Key Activities on physician-led oncology care, infusion and medication dispensing, radiation therapy, and palliative support across its outpatient network. Clinical trial screening and on-site protocol work also stayed core, helping expand access to advanced therapies close to home.
| Key activity | FY2025 signal |
|---|---|
| Outpatient oncology care | Core revenue engine |
| Radiation therapy | Used in about 50% of cancer care |
| Clinical trials | Screening and protocol execution |
What You See Is What You Get
Business Model Canvas
The preview you see is the actual The Oncology Institute, Inc. Business Model Canvas document you’ll receive after purchase. It’s not a sample or mockup—just a live view of the final file. Once your order is complete, you’ll download the same professionally formatted document, ready to use.
Resources
67 clinic locations
The Oncology Institute, Inc. operates 67 clinic locations, giving it a dense local footprint across multiple communities. That network is a core physical asset in its business model because it brings oncology care closer to patients and supports steady referral flow.
Specialist oncology physicians
Board-trained oncology physicians are The Oncology Institute, Inc.’s core clinical asset. In fiscal 2025, they drove diagnosis, therapy choice, and follow-up across complex cancer cases, where the cost of a wrong call can quickly rise.
Infusion and dispensing infrastructure
As of 2025, The Oncology Institute, Inc. uses on-site infusion rooms and dispensing to run integrated outpatient cancer care, so patients can see the doctor, get therapy, and pick up meds in one place. This clinic-based setup supports faster throughput, lower travel burden, and tighter control of drug handling across its multi-state network.
Clinical trial operations capability
The Oncology Institute, Inc.’s clinical trial operations capability is a key differentiator because it combines research workflows, trained staff, and compliance controls that let the company run advanced oncology studies. This matters in FY2025 because trial-ready operations can support access to new protocols and help the Company participate in higher-value research programs.
- Research workflows
- Clinical staff and site coordination
- Compliance and protocol oversight
- Supports advanced oncology studies
Headquarters in Cerritos, California
The Oncology Institute, Inc. is headquartered in Cerritos, California, where central administration coordinates scheduling, finance, compliance, and network support across its multi-site oncology care platform. That hub helps keep clinic operations aligned, which matters for a specialty provider serving patients across a distributed care network.
- Headquarters: Cerritos, California
- Supports scheduling and finance
- Handles compliance and network coordination
The Oncology Institute’s Core Strength: 67 Clinics, Talent, and Research
The Oncology Institute, Inc.’s key resources are its 67 clinic locations, board-trained oncology physicians, and integrated infusion and dispensing setup. In fiscal 2025, these assets supported local access, treatment delivery, and tighter control of complex cancer care.
Its clinical trial operations and Cerritos, California headquarters round out the core resource base by linking research, compliance, scheduling, finance, and network oversight across a multi-state platform.
| Resource | FY2025 detail |
|---|---|
| Clinic network | 67 locations |
| Clinical talent | Board-trained oncology physicians |
| Research capability | Clinical trial operations |
| HQ | Cerritos, California |
Value Propositions
Full-spectrum oncology care
TOI delivers full-spectrum oncology care in one network: physician visits, infusion, radiation, clinical trials, and supportive services. That five-part model cuts handoffs and keeps complex cancer care more coordinated across a patient journey that can stretch for months.
Integrated outpatient treatment model
The Oncology Institute, Inc. centers care on outpatient visits, with on-site infusion, dispensing, and support services that cut extra trips and keep treatment coordinated. This fits cancer care that is often repeated over weeks or months, so the model can improve convenience and reduce friction for patients and clinicians.
Access to clinical trials
The Oncology Institute, Inc. gives eligible patients access to clinical trials through advanced trial management, so they can get investigational options beyond standard therapy. By bringing research closer to the point of care, TOI helps make trial participation easier and more practical for patients who need it.
Support for transplant and transfusion needs
The Oncology Institute, Inc. extends care beyond routine visits with outpatient stem cell transplant and transfusion programs, serving higher-acuity oncology patients in a lower-cost setting. This matters as cancer care demand stays high, with the U.S. expected to see about 2.0 million new cancer cases in 2025.
- Outpatient transplant support
- Transfusion care for complex cases
- Helps manage higher-acuity needs
Local cancer care for adults and seniors
The Oncology Institute, Inc. focuses on adult and senior cancer patients, and its 67-location footprint makes specialty care easier to reach. Local treatment can cut travel time, support continuity with the same care team, and improve access for patients who need frequent visits.
- 67 locations improve geographic access
- Adult and senior cancer focus
- Local care reduces travel burden
- Continuity supports repeat treatment
67 Locations Deliver Coordinated Cancer Care Closer to Home
The Oncology Institute, Inc. value proposition is lower-friction cancer care: one outpatient network for visits, infusion, radiation, trials, and support. Its 67 locations improve access, while local care reduces travel and keeps treatment coordinated for patients who need repeated visits.
| Metric | Value |
|---|---|
| Locations | 67 |
| U.S. new cancer cases, 2025 | About 2.0 million |
Customer Relationships
Long-term oncology management
Long-term oncology management fits The Oncology Institute, Inc. because cancer care often spans months to years and starts with more than 2 million new U.S. cases each year. TOI builds continuity through repeated visits, labs, and treatment changes, so trust and follow-up stay central to the patient experience.
Physician-led care coordination
The Oncology Institute, Inc. uses physician-led care coordination, where oncology specialists manage treatment plans, diagnostics, and follow-up. This supports more personalized decisions and tighter alignment across therapies and supportive care.
Patient support services
The Oncology Institute, Inc. uses patient support services to help patients book visits, follow treatment steps, and handle care logistics across a complex oncology journey. This lowers friction in care coordination and supports a large, high-touch patient base seen in the latest 2025 operating period.
Trial enrollment and research support
Patients need close guidance through eligibility and consent, and TOI’s trial ops turn that into a repeatable service relationship. Only about 7% of U.S. adults with cancer join clinical trials, so education, follow-up, and plain-language communication are key to moving patients from screening to enrollment.
- Guide eligibility and consent
- Explain trial steps clearly
- Follow up through enrollment
- Support research participation
High-touch outpatient care
The Oncology Institute, Inc. uses high-touch outpatient care for infusion, transfusion, and radiation, so patients return for repeated, face-to-face visits and steady monitoring. This model drives frequent touchpoints, which is core in oncology where treatment cycles and side-effect checks need close follow-up.
- Repeated outpatient visits build loyalty
- Care teams track symptoms fast
- Service mix supports ongoing contact
High-Touch Cancer Care Fuels Repeat Patient Relationships
The Oncology Institute, Inc. keeps Customer Relationships high-touch and recurring: oncology patients often need months of visits, labs, infusions, and care changes, so trust and follow-up drive retention. In the latest 2025 operating period, that model supports frequent touchpoints across a large outpatient base.
| Customer relationship driver | Data point |
|---|---|
| U.S. cancer burden | 2M+ new cases yearly |
| Clinical trial participation | About 7% of adults with cancer |
| Care pattern | Repeated outpatient visits |
Channels
67 clinic locations
The Oncology Institute, Inc.'s 67 clinic locations are its main delivery channel, bringing hematology and oncology care to local outpatient sites. That physical network helps patients start treatment closer to home and supports retention through repeat visits, follow-up care, and ongoing therapy.
Physician and hospital referrals
Physician and hospital referrals are a core entry channel for The Oncology Institute, Inc. The U.S. is expected to see 2,041,910 new cancer cases in 2025, and referrals from community doctors and hospitals help direct these patients into specialty care, supporting patient acquisition and steady case volume.
On-site treatment facilities
In FY2025, The Oncology Institute kept infusion, dispensing, and other treatment services inside its clinic sites, so patients can move from consult to care in one system. This on-site treatment facility channel is central to service delivery because it supports faster starts, tighter care coordination, and a smoother patient flow across visits.
Clinical trial enrollment pathways
Eligible patients enter The Oncology Institute, Inc. through trial screening and research referrals, linking them to investigational therapies and feeding research enrollment. In 2025, ClinicalTrials.gov held 500,000+ studies, showing how trial access has become a core care path for oncology patients.
- Trial screening finds eligible patients.
- Referrals drive research enrollment.
- Investigational care supports TOI research.
Direct patient contact and scheduling
Patients connect with The Oncology Institute, Inc. through clinic scheduling and care-coordination teams, which keep visits, follow-ups, and treatment timing aligned. This direct contact supports ongoing engagement and helps reduce missed appointments, especially when oncology care needs repeated touchpoints over weeks or months.
- Schedules visits and follow-ups
- Coordinates treatment timing
- Supports ongoing patient engagement
Oncology Institute's 67 Clinics Streamline Cancer Care Access
The Oncology Institute, Inc. reaches patients mainly through 67 clinic sites, physician and hospital referrals, and in-clinic infusion and dispensing. These channels move cancer patients from referral to consult and treatment in one system, which supports faster starts and repeat visits.
| Channel | 2025 data |
|---|---|
| Clinic network | 67 locations |
| Market demand | 2,041,910 new U.S. cancer cases |
Customer Segments
Adult cancer patients
The Oncology Institute, Inc. serves adult oncology patients across diagnosis, active treatment, and follow-up care, and that need set drives its outpatient model. The American Cancer Society projects about 2.0 million new U.S. cancer cases in 2025, so this segment is large and steady, with recurring visits and long care cycles.
Senior cancer patients
Senior cancer patients are a core target group for The Oncology Institute, Inc.; cancer incidence rises with age, and adults 65+ account for most new U.S. cancer cases. TOI’s local clinic network supports transport-friendly access, coordinated oncology care, and added support services that older patients often need.
Patients needing infusion therapy
Patients needing infusion therapy come back for repeated, supervised oncology drug delivery, so this segment creates steady visit volume and repeat clinical touchpoints. The Oncology Institute, Inc.'s on-site infusion model is built for that pattern, making infusion a core driver of recurring care and revenue.
Patients eligible for clinical trials
Patients eligible for clinical trials are a key niche for The Oncology Institute, Inc., since only about 5% of U.S. adults with cancer join a trial, leaving room for broader access to investigational therapies. TOI’s trial management helps match eligible patients to studies, widening options beyond standard care.
- Expands care beyond standard treatment
- Supports study matching and trial ops
- Targets a small, high-need segment
Patients requiring supportive oncology services
Patients requiring supportive oncology services are a high-need segment for The Oncology Institute, Inc., especially those needing palliative care, transfusions, or outpatient stem cell transplant support. These services are common in complex cancer care, and TOI folds them into its specialty mix to keep care local, lower friction, and support recurring clinical visits.
- High-acuity, repeat-use patient base
- Includes palliative care and transfusions
- Supports outpatient transplant care
- Fits TOI’s integrated specialty model
Why Oncology Institute’s Recurring Patient Base Drives Demand
The Oncology Institute, Inc. serves adult cancer patients, with older adults making up most cases and driving repeated outpatient visits through diagnosis, treatment, and follow-up. Its core segments also include infusion, clinical-trial, and supportive-care patients, all of which need recurring, local oncology services.
| Segment | Why it matters |
|---|---|
| Adults 65+ | Most U.S. cases |
| Infusion patients | Repeat visits |
| Trial and support care | Higher-need niche |
Cost Structure
Physician and clinical labor
Physician and clinical labor is one of The Oncology Institute, Inc.’s heaviest costs because oncology care needs specialist doctors, nurses, and support staff across 67 clinic locations and multiple service lines. Keeping staffing aligned with that footprint drives compensation expense and shapes operating leverage.
Clinic occupancy and operations
Clinic occupancy and operations are a fixed-heavy cost line for The Oncology Institute, Inc. Its 67-site network means more rent, utilities, maintenance, and local admin spend as it expands access. In 2025, that footprint supported $455.2 million in revenue, but each added clinic also raises facility overhead.
Infusion drugs and medical supplies
Specialty oncology drugs and infusion supplies are one of The Oncology Institute, Inc.'s biggest cost lines, because each treatment mix drives different drug spend, wastage, and storage needs. Drug buying and tight inventory control are critical for infusion and dispensing services, and costs swing with patient volume and regimen complexity; TOI's latest filings show this remains a major pressure point.
Clinical trial administration
Clinical trial administration at The Oncology Institute, Inc. covers research staff, patient screening, documentation, compliance, and monitoring, so it is a fixed-plus-variable cost that keeps study execution running. In oncology, trial operations often absorb 20% to 30% of a study budget, and these costs are necessary to keep research capabilities active and credible.
- Staffing and coordinator time
- Screening and enrollment support
- Compliance and audit trails
- Ongoing patient monitoring
Equipment, compliance, and billing
Radiation, infusion, transfusion, and electronic record systems need steady capex and IT spend, while compliance and billing teams add fixed overhead in a tightly regulated care model. For The Oncology Institute, these costs sit at the core of service delivery, because clinical throughput and clean claims both drive cash flow.
High equipment spend, high compliance load, high billing complexity.
Cost Heavy, Margin Tight: The Oncology Institute’s 67-Clinic Model
Cost Structure for The Oncology Institute, Inc. is led by physician labor, clinic overhead, and high-cost oncology drugs, with 67 clinic sites pushing steady rent, utilities, and admin spend. In 2025, revenue reached $455.2 million, but these fixed-heavy costs keep margins tight.
| Cost driver | 2025 signal |
|---|---|
| Clinics | 67 sites |
| Revenue | $455.2 million |
| Model | Fixed-heavy, labor-intensive |
Revenue Streams
Oncology professional services
TOI’s oncology professional services, billed through healthcare reimbursement, generate recurring revenue from physician-led cancer visits and treatment management. In FY2025, this core care model remained the main cash engine, supported by frequent patient visits and ongoing therapy coordination across its community oncology network.
Infusion administration and dispensing
Infusion administration and dispensing drive The Oncology Institute, Inc. revenue by billing for in-office cancer drug delivery and on-site pharmacy fills, so volume and drug mix matter a lot. It is one of the company’s main outpatient specialty income lines, and higher treatment starts or stronger utilization can lift revenue fast.
Radiation therapy billing
Radiation therapy billing creates a separate claim stream for The Oncology Institute, Inc., because radiation treatment is billed by CPT/HCPCS code and often paid outside the core oncology visit fee. That matters: when used with chemo or other care, it broadens the reimbursement mix and can lift per-patient revenue.
Clinical trial-related revenue
The Oncology Institute, Inc. earns sponsor-funded clinical trial revenue from study operations and research payments, which helps finance its oncology research platform and offset research staff and admin costs. This stream also supports access to more trials for patients and physicians.
- Sponsor-funded trial revenue
- Research payment support
- Offsets staffing and admin costs
Supportive care reimbursement
Supportive care reimbursement at The Oncology Institute, Inc. comes from billable outpatient stem cell transplant, transfusion, and palliative care visits, which serve higher-acuity patients and add reimbursed revenue inside the specialty model. These services are a key offset to routine oncology visits because they are paid as separate care lines, not just bundled follow-up.
Billable outpatient transplant care
Separate transfusion reimbursement
Palliative care drives added revenue
Targets higher-acuity oncology needs
TOI’s Revenue Engine: Visits, Infusions, Radiation, and Trials
In FY2025, The Oncology Institute, Inc. made most revenue from reimbursed oncology visits, infusion and drug dispensing, radiation billing, and supportive care; sponsor-funded trials added a smaller, non-patient-pay stream. The mix is volume-led, so more treatment starts and higher acuity raise revenue per patient.
| Stream | FY2025 role |
|---|---|
| Professional services | Main recurring cash flow |
| Infusion/dispensing | High-margin outpatient billing |
| Radiation/supportive care | Extra reimbursed claims |
| Clinical trials | Sponsor-funded support |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.